Anaplastic Large Cell Lymphoma
Anaplastic large cell lymphoma (ALCL) is one of the most common subtypes of peripheral T-cell lymphomas (PTCLs). ALCL is an aggressive lymphoma with anaplastic lymphoma kinase-positive (ALK-positive) ALCL generally having a better prognosis and occurring in younger patients than ALK-negative ALCL. Multiagent chemotherapy, now with the addition of brentuximab vedotin, an anti-CD30 monoclonal antibody-drug conjugate, is the recommended initial therapy for ALCL with high-dose chemotherapy and autologous stem cell rescue reserved for consolidation of patients at high risk of relapse. Novel treatments targeting the universally expressed surface receptor on ALCL cells, CD30, and the ALK tyrosine kinase receptor inhibitors have provided patients with relapsed or refractory ALCL more effective treatment options.
KeywordsAnaplastic large cell lymphoma (ALCL) Anaplastic lymphoma kinase (ALK) ALK-positive ALCL ALK-negative ALCL Brentuximab vedotin (BV) CD30
- 8.Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, vol. 2. 4th ed. Geneva: International Agency for Research on Cancer; 2008.Google Scholar
- 10.Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504.CrossRefGoogle Scholar
- 26.Ceritinib with brentuximab vedotin in treating patients with ALK-positive anaplastic large cell lymphoma [Internet] 2016 Apr 6 [updated 2018 Jan 12; cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02729961.
- 27.Romidepsin and lenalidomide in treating patients with previously untreated peripheral T-cell lymphoma [Internet] 2014 Sept 5 [updated 2018 Jan 9; cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02232516.
- 30.Trial of duvelisib in combination with either romidepsin or bortezomib in relapsed/refractory T-cell lymphomas [Internet] 2016 May 26 [updated 2018 Feb 23; cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02783625.
- 32.Onalespib in treating patients with relapsed or refractory anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma [Internet] 2015 Oct 9 [updated 2018 Mar 5; cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02572453.
- 33.Study of ruxolitinib in relapsed or refractory T or NK cell lymphoma [Internet] 2016 Nov 28 [updated 2018 Mar 29; cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02974647.
- 35.Avelumab in relapsed and refractory peripheral T-cell lymphoma (AVAIL-T) [Internet] 2017 Feb 8 [updated 2017 Nov 28; cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03046953.
- 36.Nivolumab in treating patients with relapsed or refractory peripheral T-cell lymphoma [Internet] 2017 Mar 9 [updated 2017 Dec 2; cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03075553.
- 37.Durvalumab with or without lenalidomide in treating patients with relapsed or refractory cutaneous or peripheral T cell lymphoma [Internet] 2017 Jan 5 [updated 2017 Nov 30; cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03011814.
- 38.Study of pembrolizumab combined with decitabine and pralatrexate in PTCL and CTCL [Internet] 2017 Aug 7 [updated 2018 Mar 8; cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03240211.
- 41.ALRN-6924 in patients with advances solid tumors or lymphomas [Internet] 2014 Oct 15 [updated 2017 Jun 27; cited 2018 Apr 9]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02264613.
- 42.Horwitz SM, Hamadani M, Fanale MA, et al. Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma. Blood. 2017;130:1510.Google Scholar